Skip to content

G&A at other companies

Teladoc Health logo
Teladoc HealthTDOC
$102.09M-9.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.98M-0.7%
AdaptHealth logo
AdaptHealthAHCO
$95.91M+10.4%
Hinge Health, Inc. logo
Hinge Health, Inc.HNGE
$23.02M+36.4%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$13.28M+13.1%

Other financials

Income statement

See full
Revenue$78.0M+42.0%
Gross profit$48.7M+52.6%
Operating income-$4.8M+43.1%
Net income-$3.0M+68.6%
EPS (diluted)-$0.05+95.7%

Balance sheet

See full
Cash & equivalents$211.8M+257%
Total debt$30.0M
Total equity$234.1M+160%
Total assets$302.8M

Cash flow

See full
Operating cash flow-$11.8M+26.6%
CapEx$78.0K-75.2%
Free cash flow-$11.9M+27.5%

Valuation

See full
Market cap$1.11B+23.8%
P/S3.9×-0.4×

Profitability

See full
Gross margin66.3%+4.4pp
Operating margin-9.6%-4.0pp
Net margin-11.3%-4.6pp
FCF margin-40.8%

Returns & leverage

See full
Return on equity26.8%
Debt / equity0.1×
Current ratio3.9×

Where this comes from

Reported directly by OMDA in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: OMDA’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about OMDA's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OMDA's G&A?
OMDA (OMDA) reported G&A of $13.99M in Q1 2026.
How has OMDA's G&A changed year-over-year?
OMDA's G&A increased by 23.6% year-over-year, from $11.32M to $13.99M.
What is the long-term trend for OMDA's G&A?
Over 2 years (2023 to 2025), OMDA's G&A has grown at a 20.4% compound annual growth rate (CAGR), from $35.98M to $52.18M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.